A Phase I/II trial of OBI-3424

Trial Profile

A Phase I/II trial of OBI-3424

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2018

At a glance

  • Drugs OBI 3424 (Primary)
  • Indications Liver cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 09 Jul 2018 Status changed from planning to recruiting, according to an OBI Pharma media release.
    • 19 Apr 2018 According to an OBI Pharma media release, the FDA has approved the IND application for Phase I/II study of OBI-3424. This trial will be conducted at the University of Texas M.D. Anderson Cancer Center and The James Cancer Hospital and Solove Research Institute of Ohio State University.
    • 01 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top